Hospital
Aspirus Iron River Hospital & Clinics, INC.
Aspirus Iron River Hospital & Clinics, INC. was paid $5.76M by Medicaid between Jan 2018 and Dec 2024, across 118 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoASPIRUS IRON RIVER HOSPITAL & CLINICS, INC.
IRON RIVER, MI 49935
IRON RIVER, MI 49935
33aNPI1497750830assigned 06/14/2005
33bProvider typeCritical Access Hospital
28Total paid$5.76M
24GClaims161,773
24DCodes billed118
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#17 of 31
Median peer was paid$6.03M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,553 | $729K | |
| 2019 | 23,534 | $572K | |
| 2020 | 18,811 | $648K | |
| 2021 | 24,901 | $937K | |
| 2022 | 23,419 | $907K | |
| 2023 | 25,188 | $1.00M | |
| 2024incomplete | 20,367 | $964K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 13,063 | 9,143 | $1.30M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 8,135 | 5,511 | $1.26M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 12% | 8,215 | 6,330 | $665K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 1,634 | 1,322 | $397K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.4% | 2,778 | 2,232 | $314K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.0% | 7,158 | 2,077 | $229K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 1,351 | 711 | $175K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 1,642 | 1,558 | $111K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 957 | 762 | $105K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 2,281 | 1,847 | $91K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 587 | 314 | $87K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 2,151 | 1,872 | $87K |
106 more codes
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.4% | 786 | $81K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 2,977 | $77K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 2,745 | $71K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 1,606 | $59K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 984 | $53K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,967 | $52K |
| 80053 | Comprehensive metabolic panel | <1% | 11,750 | $44K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,055 | $42K |
| 80061 | Lipid panel | <1% | 3,762 | $39K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,176 | $38K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,313 | $32K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 559 | $26K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 780 | $25K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 642 | $25K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,385 | $24K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,352 | $24K |
| 93976 | <1% | 543 | $23K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 949 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,379 | $14K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 710 | $13K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,043 | $13K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 208 | $11K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 99 | $10K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,673 | $8K |
| 82607 | <1% | 797 | $7K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 448 | $7K |
| 97162 | <1% | 83 | $7K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 227 | $6K |
| 83735 | <1% | 2,854 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 242 | $5K |
| 72110 | <1% | 179 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 228 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,511 | $4K |
| 84439 | <1% | 794 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 25 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,207 | $4K |
| 80306 | <1% | 1,112 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,377 | $3K |
| 73564 | <1% | 115 | $3K | |
| 87070 | <1% | 1,559 | $3K | |
| 85610 | <1% | 1,973 | $3K | |
| 73610 | <1% | 232 | $3K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 51 | $3K |
| 81001 | <1% | 4,541 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 800 | $2K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 28 | $2K |
| 73030 | <1% | 137 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,499 | $2K |
| 73630 | <1% | 169 | $2K | |
| 83690 | <1% | 1,965 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 80 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 844 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 25 | $1K |
| 97161 | <1% | 39 | $1K | |
| 84484 | <1% | 1,554 | $1K | |
| 86140 | <1% | 578 | $1K | |
| 87088 | <1% | 352 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 36 | $925.22 |
| 73130 | <1% | 75 | $862.64 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 13 | $796.94 |
| 97035 | <1% | 90 | $761.56 | |
| 73110 | <1% | 33 | $744.37 | |
| 83605 | <1% | 956 | $720.61 | |
| 87077 | <1% | 319 | $715.09 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 20 | $650.36 |
| 81025 | <1% | 1,153 | $619.25 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 25 | $616.12 |
| 82043 | <1% | 150 | $559.15 | |
| 84481 | <1% | 42 | $481.57 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 25 | $426.20 |
| 87186 | <1% | 128 | $378.65 | |
| 85651 | <1% | 202 | $355.34 | |
| 86803 | <1% | 37 | $291.62 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 15 | $273.65 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 26 | $235.60 |
| 82746 | <1% | 27 | $227.85 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 103 | $225.76 |
| 82728 | <1% | 28 | $223.52 | |
| 84153 | <1% | 12 | $152.57 | |
| 84703 | <1% | 162 | $107.24 | |
| 85027 | <1% | 27 | $80.85 | |
| 83550 | <1% | 12 | $58.05 | |
| 83880 | <1% | 14 | $57.94 | |
| 83540 | <1% | 12 | $42.93 | |
| 85730 | <1% | 44 | $39.12 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 20 | $36.21 |
| 82948 | <1% | 122 | $35.33 | |
| 87807 | <1% | 27 | $29.16 | |
| 82550 | <1% | 31 | $27.79 | |
| 87040 | <1% | 26 | $26.32 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,484 | $24.25 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,650 | $13.71 |
| 82962 | <1% | 23 | $3.30 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 1,958 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 29 | $0.00 |
| 94664 | 0% | 123 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 40 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 37 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 940 | $0.00 |
| 96376 | 0% | 28 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 35 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 268 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 43 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 55 | $0.00 |
| 94760 | 0% | 14 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.